Information  X 
Enter a valid email address

Destiny Pharma PLC (DEST)

  Print   

Thursday 10 June, 2021

Destiny Pharma PLC

Director Dealing

RNS Number : 5504B
Destiny Pharma PLC
10 June 2021
 

 

 

 

Destiny Pharma plc

 

("Destiny Pharma" or the "Company")

 

Director Dealing

 

 

Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it was notified on 10 June 2021 that on that same day, Dr William Love, Chief Scientific Officer of the Company, sold 350,000 ordinary shares of 1 pence in the Company ("Ordinary Shares") at a price of 120 pence.

Following the sale, Dr William Love's beneficial interest in the Company is 6,509,500 Ordinary Shares, representing 10.87 per cent. of the total issued share capital.  Dr Love confirms that he does not intend to sell any further Ordinary Shares for the foreseeable future, that is until 2023 at the earliest.

 

Enquiries:

Destiny Pharma plc

+44 (0) 1273 704 440

Neil Clark, CEO
Shaun Claydon, CFO


finnCap Limited - Nominated Adviser and Joint Broker

+44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)
Alice Lane (ECM)


WG Partners LLP - Joint Broker

+44 (0) 20 3705 9330

Nigel Barnes / Claes Spång / Nigel Birks


Optimum Strategic Communications

+44 (0) 203 174 1789

Mary Clark / Shabnam Bashir / Manel Mateus

 

 


 

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

 

For further information, please visit  https://www.destinypharma.com

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dr William Love

2. 

Reason for the Notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/Amendment

Initial Notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Destiny Pharma plc

b)

LEI

213800O9WH9Z38EHAC95

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 1p each ("Ordinary Shares")

Identification code

DEST  GB00BDHSP575

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)


Price(s)

Volume(s)

Sold

120 pence

350,000

d)

Aggregated information:

· Aggregated volume

· Price

 

See 4c) above

e)

Date of the transaction

10 June 2021

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFEERLIILIL

a d v e r t i s e m e n t